Insider Selling: BioTelemetry Inc. (BEAT) SVP Sells 1,061 Shares of Stock
BioTelemetry Inc. (NASDAQ:BEAT) SVP George Hrenko sold 1,061 shares of BioTelemetry stock in a transaction on Monday, September 19th. The shares were sold at an average price of $18.50, for a total value of $19,628.50. Following the completion of the sale, the senior vice president now directly owns 37,568 shares of the company’s stock, valued at $695,008. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
George Hrenko also recently made the following trade(s):
- On Thursday, September 8th, George Hrenko sold 3,491 shares of BioTelemetry stock. The shares were sold at an average price of $18.06, for a total value of $63,047.46.
- On Wednesday, August 24th, George Hrenko sold 7,473 shares of BioTelemetry stock. The shares were sold at an average price of $20.11, for a total value of $150,282.03.
- On Tuesday, August 23rd, George Hrenko sold 3,165 shares of BioTelemetry stock. The shares were sold at an average price of $20.67, for a total value of $65,420.55.
- On Monday, August 22nd, George Hrenko sold 4,149 shares of BioTelemetry stock. The shares were sold at an average price of $20.85, for a total value of $86,506.65.
Shares of BioTelemetry Inc. (NASDAQ:BEAT) opened at 18.22 on Wednesday. BioTelemetry Inc. has a 52 week low of $8.74 and a 52 week high of $21.42. The firm has a market capitalization of $510.62 million, a PE ratio of 38.77 and a beta of 0.81. The company’s 50 day moving average price is $19.63 and its 200-day moving average price is $16.08.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/insider-selling-biotelemetry-inc-beat-svp-sells-1061-shares-of-stock.html
BioTelemetry (NASDAQ:BEAT) last released its earnings results on Tuesday, August 2nd. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.03. BioTelemetry had a return on equity of 25.36% and a net margin of 7.11%. The firm earned $52.68 million during the quarter, compared to analysts’ expectations of $50.27 million. During the same period in the prior year, the company earned $0.12 earnings per share. The company’s quarterly revenue was up 17.6% on a year-over-year basis. On average, equities research analysts expect that BioTelemetry Inc. will post $0.76 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in BEAT. DIAM Co. Ltd. acquired a new stake in BioTelemetry during the second quarter valued at $133,000. Acrospire Investment Management LLC boosted its stake in BioTelemetry by 147.9% in the second quarter. Acrospire Investment Management LLC now owns 8,214 shares of the company’s stock valued at $134,000 after buying an additional 4,900 shares during the last quarter. Bank of Montreal Can acquired a new stake in BioTelemetry during the second quarter valued at $164,000. BlackRock Inc. boosted its stake in BioTelemetry by 691.2% in the second quarter. BlackRock Inc. now owns 11,448 shares of the company’s stock valued at $187,000 after buying an additional 10,001 shares during the last quarter. Finally, First Quadrant L P CA boosted its stake in BioTelemetry by 56.4% in the second quarter. First Quadrant L P CA now owns 12,200 shares of the company’s stock valued at $199,000 after buying an additional 4,400 shares during the last quarter. Hedge funds and other institutional investors own 78.28% of the company’s stock.
A number of brokerages recently commented on BEAT. Sidoti began coverage on BioTelemetry in a research note on Tuesday, September 13th. They set a “buy” rating and a $27.00 price objective for the company. Benchmark Co. lifted their price objective on BioTelemetry from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, August 3rd. Finally, Zacks Investment Research cut BioTelemetry from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 26th.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.